This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Journals
    Journal
    30/05/19

    Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease.

    Background: Hyperinsulinemia aggravates insulin resistance and cardio-vascular disease. How the insulinotropic glucagon-like peptide-1 receptor agonist liraglutide in a physiologic post-prandial setting may act on pancreatic alpha and beta-cell function in patients with coronary artery disease (CAD) and type 2 diabetes (T2DM) is less clear.

    • Source: Diabetology & Metabolic Syndrome
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    25/08/15

    Phase III results for Victoza (liraglutide) in type 1 diabetes- Novo Nordisk

    Novo Nordisk announced headline results from the second and final Phase IIIa trial with Victoza (liraglutide) as adjunct therapy to...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    03/12/15

    Meta-analysis of Victoza (liraglutide) trials demonstrates efficacy in type 2 diabetes- Novo Nordisk

    New findings from a network meta-analysis show that treatment with Victoza (liraglutide), from Novo Nordisk, provides a greater HbA1c reduction...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    06/11/15

    SCALE Phase IIIa trial for Saxenda (liraglutide) results in three year weight loss- Novo Nordisk

    New data from the phase IIIa SCALE (Satiety and Clinical Adiposity: Liraglutide Evidence in Non-Diabetic and Diabetic adults) Obesity and...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    07/08/16

    LEADER study of Victoza (liraglutide) shows some risks for diabetic patients with heart failure- Novo Nordisk

    New data from LEADER, a a Phase II study of Victoza (liraglutide), from Novo Nordisk, published in the Journal of...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    16/05/14

    Successful Phase III SCALET trial for liraglutide for Obesity treatment - Novo Nordisk

    Results from the SCALET Obesity and Pre-diabetes phase IIIa trial will be presented on 16 May, 2014 for the first...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    04/04/16

    Phase III SCALE trial of Saxenda (liraglutide shows benefits in obesityy- Novo Nordisk

    New data from the three-year part of the phase IIIa SCALE Obesity and Prediabetes trial of Saxenda (liraglutide 3 mg),...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    07/01/14

    Novo Nordisk files liraglutide at FDA and EMA for treatment of Obesity

    Novo Nordisk has announced two separate regulatory submissions for a 3 mg dose of liraglutide, a once-daily human GLP-1 analogue,...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    03/04/16

    Trial of Victoza (liraglutide) shows superiority to sitagliptin in type 2 diabetes -Novo Nordisk

    Findings from a clinical trial (LIRA-SWITCH) of 407 adults with type 2 diabetes comparing Victoza (liraglutide 1.8 mg), from Novo...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    23/11/16

    FDA approves Xultophy 100/3.6 (insulin degludec plus liraglutide) to treat type 2 diabetes.-Novo Nordisk

    Novo Nordisk announced that the FDA has approved the New Drug Application (NDA) for Xultophy 100/3.6.(iDegLira in the EU). Xultophy...

    See more